United Therapeutics Corporation (NASDAQ:UTHR) drug manufacturer, is reporting third quarter earnings results on Wednesday 28th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 2.78 per share.
For the full year, analysts predict revenues of $ 1424.51 million, while looking forward to income of $ 11.39 per share.
Previous Quarter Performance
United Therapeutics Corporation unfold income for the second quarter of $ 3.68 per share, from the revenue of $ 362.00 million. The quarterly earnings dropped 21.03 percent while revenues declined 3.10 percent compared with the same quarter last year.
According to street consensus, UTHR was expected to report 2Q20 income of $ 2.86 per share from revenue of $ 339.97 million. The bottom line results beat street analysts by $ 0.82 or 28.67 percent, at the same time, top line results outshined analysts by $ 22.03 million or 6.48 percent.
Stock Performance
Shares of United Therapeutics Corporation traded low $ -0.17 or -0.14 percent on Tuesday, reaching $ 123.40 with volume of 457.70 thousand shares. United Therapeutics Corporation has traded high as $ 124.50 and has cracked $ 121.48 on the downward trend
According to the previous trading day, closing price of $ 123.40, representing a 63.50 % increase from the 52 week low of $ 75.58 and a 3.3 % decrease over the 52 week high of $ 127.79.
The company has a market capital of $ 5.48 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
United Therapeutics Corporation will be hosting a conference call at 9:00 AM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.unither.com
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The companys commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases.
